

An innovative approach for diabetes therapy....

Our Accomplishments



Glucose Measurement

We used spectrophotometric methods to measure glucose concentrations. Spectrophotometry is based off of Beer-Lamberts law i.e. concentration of analyte in solution is proportional to the analyte absorbance at a certain wavelength.


$$A = \epsilon bc$$

In order to use the traditional spectrophotometers which have a wavelength range of up to 1500nm, we implemented a method involving a glucose solution with Benedict's reagent.



Spectrophotometric methods using Krebs'/Benedict's solution have yielded standardized curves at 500nm and 734nm wavelengths:




Interstitial fluid Extraction




The team produced a new design which uses an aluminum (Al) plate with a gasket to ensure that vacuum pressure works effectively. We introduced perforations to the plate to increase device stability and prevent the skin from being sucked into the vacuum device. A PVC pipe end was incorporated to allow a watertight seal with the skin.



Scything the fat from pig skin.



Application of vacuum on pig skin



1) Pig skin before experiment 2) Pig skin after iontophoresis, sonophoresis and application of vacuum.

The images above were taken under a compound microscope at 20 xs. There was a significant difference in the pig skin before and after the experiment. Due to poor resolution and a lack of necessary equipment, we are unable to positively identify pores.



Dr. Deboth, Co-instructor



Dr. Opara, Instructor



Kochanek, Malgorzata PSYCH/ BIO



Goldstein, Linda, TC



Babicz, Amanda, AE



Morley, Michael, BME



Mesquita, Walatta-Tseyon, MBB



Mathews, Rohan, EE



Narasimhan, Dev, BME



Patel, Bhavin, BME



Rahnavard, Amir, BME



Saung, E-Fann, ME



Riaz, Maryum, BME



Reddy, Kirithi, EE/ BIO



Thomas, David, MBB

ACKNOWLEDGEMENTS:

We would like to thank Dr. Opara and Prof. Deboth for their endless support and encouragement, the IPRO office for their assistance, Dr Dhar for permitting us to use her lab, Dr Bishnoi for her invaluable advice and all our supporters for helping us make this IPRO a success.

What Is Diabetes?

Diabetes is a condition which is defined by the inability of the body to produce or utilize insulin. There are two major types of diabetes: Type I and Type II. In an individual with Type I diabetes, the pancreas is unable to produce insulin. An individual with Type II diabetes is able to produce insulin, but the body's tissue cells are resistant to it.

How Is Diabetes Inconvenient To Your Life?

Current therapy for Type I diabetes requires multiple daily venipunctures for insulin delivery in response to changes in blood glucose concentrations. This treatment modality is both inconvenient and painful.

- ❖ **Sleeping:** glucose levels must be checked during the night to avoid slipping into a hypoglycemic coma
- ❖ **Eating:** meals have to be scheduled and they can only contain a calculated amount of carbohydrates
- ❖ **Exercising:** too much insulin during exercise can lead to a hypoglycemic coma
- ❖ **Social Activities:** leaving to check glucose levels or injecting yourself with glucose poses an awkward situation at parties or a restaurant.

Objectives:

In previous semesters, members of this IPRO researched options for glucose measurement and insulin delivery. This semester we sought to:

1. Use a **non-invasive method for extraction** in order to extract a greater amount of interstitial fluid than achieved before.
2. Revise the prototype in order to improve vacuum efficiency.
3. Weigh the advantages and disadvantages of different glucose measuring techniques investigated and select the most effective one.
- Set up an experimental design using **Benedict's solution to test for glucose concentrations.**
4. Research and apply for **NCIIA and FORD grants.**

Market Opportunity:

Millions of Americans use insulin therapy to treat their diabetes. As such, the treatment market is exceptionally large, with estimates ranging from \$44 billion to \$100 billion per year. We believe that our innovative design of a self-automated, non-invasive insulin delivery and glucose monitoring system will prove very competitive in this substantial market.

What will our prototype comprise of?

